These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 18154212

  • 1. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME.
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [Abstract] [Full Text] [Related]

  • 2. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G, Panariello L, Cacciapuoti S, Bianca D, Ayala F.
    Dermatitis; 2012 Oct; 23(5):237-8. PubMed ID: 23010833
    [Abstract] [Full Text] [Related]

  • 3. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA, Balagula Y, Lacouture ME, Anadkat MJ.
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A.
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [Abstract] [Full Text] [Related]

  • 8. [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports].
    Rodarte CM, Abdallah OA, Barbosa NF, Koch Lde O, Resende UM.
    An Bras Dermatol; 2009 Aug; 84(6):667-70. PubMed ID: 20191181
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R, Werfel T, Kapp A, Elsner J.
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I, David M, Stemmer SM.
    Oncologist; 2010 Jun; 15(9):1002-8. PubMed ID: 20709888
    [Abstract] [Full Text] [Related]

  • 15. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D, Martinac I, Ledić Drvar D, Čeović R, Bilić I, Marinović B.
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME, Melosky BL.
    Skin Therapy Lett; 2007 Apr; 12(6):1-5. PubMed ID: 17762902
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J, Pomeranz MK.
    Dermatol Online J; 2007 Jan 27; 13(1):1. PubMed ID: 17511934
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.